Arrhythmia Research Technology, Inc. Declares Cash Dividend
FITCHBURG, MA -- (MARKET WIRE) -- 01/25/12 -- Arrhythmia Research Technology, Inc. (the "Company") (NYSE Amex: HRT) announced that its Board of Directors declared a quarterly cash dividend of $0.03 per share. The dividend will be paid to holders of record on February 15, 2012, payable on March 1, 2012.
James E. Rouse, President and CEO, stated, "The Board of Directors' decision to change to a quarterly dividend rather than semi-annual dividend going forward is consistent with most dividend paying companies. Moving to a quarterly dividend aligns earnings and cash flow with quarterly reporting and should make it easier for analysts and investors to analyze company performance. The Company initiated a $0.12 per year dividend paid semi-annually in 2010."
About Arrhythmia Research Technology, Inc.
The Company through its wholly-owned subsidiary, Micron Products, Inc., manufactures silver plated and non-silver plated conductive resin sensors and distributes metal snaps used in the manufacture of disposable ECG, EEG, EMS and TENS electrodes. Micron's MIT (MTF) division provides end-to-end product life cycle management through a comprehensive portfolio of value-added services such as design, engineering, prototyping, manufacturing, machining, assembly and packaging. MIT manufactures custom injection molded products for medical, electronic, industrial and consumer applications, and provides high end mold design, manufacturing and precision machining for various industries. The Company's wholly-owned subsidiary, RMDDxUSA Corp. and its Canadian subsidiary, RMDDx Corporation, branded "WirelessDx", is dedicated to the development and commercialization of medical devices and services, medical information technology, medical diagnostics and remote patient monitoring through wireless, Internet and telecommunication technologies. The Company's products also include a customizable proprietary signal-averaging electrocardiography (SAECG) software used in the detection of potentially lethal heart arrhythmias and that is reconfigurable for a variety of hardware platforms.
For more information please check our websites:
Forward-looking statements made herein are based on current expectations of the Company that involve a number of risks and uncertainties and should not be considered as guarantees of future performance. The factors that could cause actual results to differ materially include our ability to maintain our current pricing model and/or decrease our cost of sales; our ability to increase sales of higher margin products and services; variations in the mix of products and services sold; variability of customer delivery requirements; ability to license our software, provide timely customization and updates; ability to successfully market WirelessDx services, manage the timing of investment in operational infrastructure and ability to accelerate the pace of revenues from customer implementation; a stable interest rate market and/or a stable currency rate environment in the world, and specifically the countries where we are doing business; continued availability of supplies or materials used in manufacturing at competitive prices; volatility in commodity and energy prices; and the Company's ability to offset higher costs with price increases. More information about factors that potentially could affect the Company's financial results is included in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2010.
Contact: David Garrison Website: http://www.arthrt.com (978) 345-5000
Source: Arrhythmia Research Technology, Inc.